This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Neridronic Acid is a bisphosphonate drug that prevents osteoclastic bone resorption which is used for the prevention and treatment of osteoporosis.
- Generic Name
- Neridronic Acid
- DrugBank Accession Number
- DB11620
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Structure
Structure for Neridronic Acid (DB11620)
- Weight
- Average: 277.15
Monoisotopic: 277.048025887 - Chemical Formula
- C6H17NO7P2
- Synonyms
- (6-amino-1-hydroxyhexylidene)diphosphonic acid
- Neridronate
- Neridronic Acid
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Neridronate sodium H6JVB49Q0F 80729-79-9 MHYULJPRWPTMTD-UHFFFAOYSA-M
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Organic phosphonic acids and derivatives
- Sub Class
- Bisphosphonates
- Direct Parent
- Bisphosphonates
- Alternative Parents
- Organic phosphonic acids / Organopnictogen compounds / Organophosphorus compounds / Organooxygen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives
- Substituents
- Aliphatic acyclic compound / Amine / Bisphosphonate / Hydrocarbon derivative / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound / Organooxygen compound / Organophosphonic acid
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 8U27U3RIN4
- CAS number
- 79778-41-9
- InChI Key
- PUUSSSIBPPTKTP-UHFFFAOYSA-N
- InChI
- InChI=1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14)
- IUPAC Name
- (6-amino-1-hydroxy-1-phosphonohexyl)phosphonic acid
- SMILES
- NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O
References
- General References
- AIFA Product Information: Nerixia (neridronic acid) for intravenous injection [Link]
- External Links
- PubChem Compound
- 71237
- PubChem Substance
- 347828013
- ChemSpider
- 64372
- BindingDB
- 50098383
- ChEBI
- 135145
- ChEMBL
- CHEMBL55214
- ZINC
- ZINC000001999491
- PDBe Ligand
- NRD
- PDB Entries
- 5er8 / 7kje / 7kjf
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Complex Regional Pain Syndrome (RSD) 1 3 Terminated Treatment Complex Regional Pain Syndrome (RSD) 2 2 Completed Treatment Osteoporosis / Thalassemia Intermedia (TI) / Thalassemia Major 1 2 Unknown Status Treatment Osteoarthritis of the Knee 1 2, 3 Completed Treatment Complex Regional Pain Syndrome Type 1 (CRPS) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intravenous 25 MG Injection, solution, concentrate Intravenous 100 MG - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 13.5 mg/mL ALOGPS logP -1 ALOGPS logP -3.4 Chemaxon logS -1.3 ALOGPS pKa (Strongest Acidic) 0.69 Chemaxon pKa (Strongest Basic) 10.21 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 6 Chemaxon Polar Surface Area 161.31 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 56.58 m3·mol-1 Chemaxon Polarizability 23.15 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at August 26, 2016 16:09 / Updated at May 05, 2021 20:31